A study to compare effectiveness of Body-weight based vs Body-surface area based prednisolone regimen in children with nephrotic syndrome, a chronic protein losing kidney disease.

Efficacy of Body-weight based vs Body-surface area based prednisolone regimen in Idiopathic Nephrotic Syndrome: A Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/03/005655

Enrollment

Registered

2015-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nephrotic Syndrome

Interventions

Intervention1: Prednisolone body weight-based: Prednisolone shall be administered orally as body weight-based (2mg/kg/day) regimen orally in two/three divided doses till remission for relapses or till

Eligibility

Inclusion criteria

Inclusion criteria: (1) Age-2 to 12years (2) Idiopathic Nephrotic Syndrome (3) Either first episode nephritic syndrome or infrequent relapse nephrotic syndrome

Exclusion criteria

Exclusion criteria: (1) Congenital nephrotic syndrome (2) Previous history of receiving any immunosuppressant other than prednisolone (3) Steroid resistant nephritic syndrome (4) Steroid dependant nephrotic syndrome (5) Secondary causes of nephrotic syndrome

Design outcomes

Primary

Measure	Time frame
Relapse free survival over 6 monthsTimepoint: 3 and 6 month	—

Secondary

Measure	Time frame
Time taken for initial remission, adverse effects of steroids, cumulative dosage of prednisolone.Timepoint: 3 and 6 month	—

Countries

India

Contacts

Public ContactBiswanath Basu

NRS Medical College and Hospital

basuv3000@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 28, 2026